ImmuneInvestigational

Imuthiol (Diethyldithiocarbamate)

Intravenous, Oral

Overview

Imuthiol is the sodium salt of diethyldithiocarbamate, a small molecule rather than a peptide, historically explored for immune modulation and antiviral properties. It is thought to alter cytokine profiles and scavenge reactive oxygen species.

Mechanism of Action

Therapeutic interest has focused on HIV infection and other states of immune dysregulation..

Research Summary & Key Findings

Early clinical trials in the late 1980s and early 1990s investigated imuthiol in HIV-positive patients, with some studies reporting transient increases in CD4 counts but no durable virologic or clinical benefit. Subsequent development was discontinued due to lack of efficacy in later-stage trials.

Clinical Status

Investigational

Imuthiol (Diethyldithiocarbamate) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

IntravenousOral

Related Peptides in Immune

Find a Provider

Find a verified provider who offers Imuthiol (Diethyldithiocarbamate) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Imuthiol (Diethyldithiocarbamate).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.